Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug 1;19(2):2228162.
doi: 10.1080/21645515.2023.2228162.

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study

Miwa Haranaka  1 , Makoto Yono  2 , Hiroyuki Kishino  3 , Rie Igarashi  3 , Nobuyuki Oshima  3 , Miyuki Sawata  3 , Heather Loryn Platt  4
Affiliations
Clinical Trial

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study

Miwa Haranaka et al. Hum Vaccin Immunother. .

Abstract

V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult pneumococcal disease after the introduction of pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly prevalent in adult invasive pneumococcal disease (IPD). This Phase I study assessed the safety, tolerability, and immunogenicity of V116 in Japanese adults. Participants ≥20 years of age were randomized to receive a single dose of V116 or 23-valent pneumococcal polysaccharide vaccine (PPSV23) at day 1. Outcomes were solicited injection-site and systemic adverse events (AEs) from day 1 to day 5, vaccine-related serious AEs from day 1 through day 30, and serotype-specific opsonophagocytic antibody (OPA) titers and immunoglobulin G (IgG) concentrations at day 30. Overall, 102 participants were randomized 1:1 to each group. Comparable proportions vaccinated with V116 and PPSV23 experienced ≥1 solicited injection-site AE and ≥1 solicited systemic AE. The most common injection-site AEs were injection-site pain (V116: 54.9%; PPSV23: 66.7%) and swelling (V116 and PPSV23: 13.7%), and the most common systemic AEs were myalgia (V116: 17.6%; PPSV23: 19.6%) and fatigue (V116: 13.7%; PPSV23: 9.8%). Solicited AEs were mostly mild and of ≤3 days duration. No vaccine-related serious AEs or deaths were reported. The OPA and IgG findings showed that the immunogenicity of V116 and PPSV23 were comparable for the 12 common serotypes and V116 was more immunogenic for the nine unique serotypes compared with PPSV23. V116 was well tolerated, with a safety profile similar to PPSV23, and induced functional antibodies against all 21 serotypes.

Keywords: 21-valent; Japanese; V116; adults; immunogenicity; pneumococcal conjugate vaccine; pneumococcal disease; safety; tolerability.

PubMed Disclaimer

Conflict of interest statement

H.P. is an employee of Merck & Co., Inc., Rahway, NJ, USA and may own stock and/or stock options in Merck & Co., Inc., Rahway, NJ, USA. H.K., N.O., M.S., R.I. are employees of MSD K.K., Tokyo, Japan and may own stock and/or stock options in Merck & Co., Inc., Rahway, NJ, USA. M.H. and M.Y. have no conflicts of interest to report.

Figures

Figure 1.
Figure 1.
Proportions of participants with solicited AEs graded by maximum intensity. Solicited AEs were collected post-vaccination on days 1 through 5 after vaccination with V116 (n = 51) or PPSV23 (n = 51). The height of the stacked bar represents the total percentage of participants reporting the AE. The severity grades (mild or moderate) within the bar indicate the proportion of the total attributed to each respective category. No events were graded as severe.
Figure 2.
Figure 2.
Estimated OPA GMT ratios 30 days after vaccination for (a) the 12 serotypes common to V116 and PPSV23 and (b) the nine serotypes unique to V116.
See this image and copyright information in PMC

References

    1. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–8. doi:10.1016/S0140-6736(16)31012-1. - DOI - PMC - PubMed
    1. Yanagihara K, Kosai K, Mikamo H, Mukae H, Takesue Y, Abe M, Taniguchi K, Petigara T, Kaku M.. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan. Int J Infect Dis. 2021;102:260–8. doi:10.1016/j.ijid.2020.10.017. - DOI - PubMed
    1. Fukusumi M, Chang B, Tanabe Y, Oshima K, Maruyama T, Watanabe H, Kuronuma K, Kasahara K, Takeda H, Nishi J, et al. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution. BMC Infect Dis. 2017;17(1):2. doi:10.1186/s12879-016-2113-y. - DOI - PMC - PubMed
    1. Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K, Adult Pneumonia Study Group - Japan (APSG-J). The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10(3):e0122247. doi:10.1371/journal.pone.0122247. - DOI - PMC - PubMed
    1. Weinberger DM, Shapiro ED. Pneumococcal vaccines for adults: what’s next? Clin Infect Dis. 2020;70:2493–5. doi:10.1093/cid/ciz743. - DOI - PubMed

Publication types